女性膀胱癌根治性膀胱切除术中保留盆腔器官与标准术式的肿瘤学与功能结局系统综述
该系统综述纳入15项研究共874例接受保留盆腔器官根治性膀胱切除术(POPRC)或标准根治性膀胱切除术(RC)并原位新膀胱替代的女性膀胱癌患者,发现POPRC在肿瘤学结局上可能不劣于标准RC,同时改善性功能和排尿功能,但证据质量低且异质性大。
要点
- POPRC组术后6个月内86%(167/194)恢复性活动,性满意度中位数88.5%(范围80-100%)。
- 3年和5年癌症特异性生存率分别为70-100%和65-100%,总生存率分别为65-100%。
- 日间和夜间控尿率分别为58-100%和42-100%,自我导尿率为9.5-78%。
核心结论
- 对于经过良好选择的患者,POPRC联合原位新膀胱可能在肿瘤学结局上与标准RC相当,同时改善性功能和排尿功能结局。
- 然而,接受RC的女性中POPRC的肿瘤学和功能数据仍不成熟,需要在前瞻性对照环境中进一步评估。
研究设计与样本
- 系统综述,检索Medline、Embase、Cochrane对照试验数据库和clinicaltrial.gov,纳入前瞻性和回顾性比较研究及单臂病例系列。
- 共纳入15项研究(15篇文章),总样本量874例患者;其中3篇为配对研究设计,其余主要为小型回顾性病例系列。
- 主要结局为术后6-12个月的性功能和>2年的肿瘤学结局(疾病复发和总生存);次要结局为6-12个月的控尿功能。
- 采用标准Cochrane综述方法进行偏倚风险评估,包括基于混杂评估的附加领域。
主要发现
- 7项研究报告性结局,167/194例患者(86%)在术后6个月内恢复性活动,性满意度评分中位数(范围)为88.5%(80-100%)。
- 7项研究报告生存结局(197例患者),平均随访12至132个月;3年和5年癌症特异性生存率分别为70-100%和65-100%,总生存率分别为65-100%。
- 11项研究报告控尿结局,日间控尿率为58-100%,夜间控尿率为42-100%,自我导尿率为9.5-78%。
- 由于报告质量差和研究间异质性大,未进行亚组分析,而采用叙述性综合方法;所有研究的总体偏倚风险均为高。
临床怎么用
- 对于经过良好选择的女性膀胱癌患者,POPRC联合原位新膀胱可能考虑用于改善性功能和排尿功能结局,但原文强调数据仍不成熟,需要前瞻性对照研究进一步评估。
局限性
- 除3篇配对研究外,其余研究主要为小型回顾性病例系列。
- 由于报告质量差和研究间异质性大,未进行亚组分析而采用叙述性综合。
- 所有研究的总体偏倚风险均为高。
- POPRC的肿瘤学和功能数据仍不成熟,需要在前瞻性对照环境中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pelvic organ-preserving radical cystectomy (POPRC) for women may improve postoperative sexual and urinary functions without compromising the oncological outcome compared with standard radical cystectomy (RC). OBJECTIVE: To determine the effect of POPRC on sexual, oncological and urinary outcomes compared with RC in women who undergo standard curative surgery and orthotopic neobladder substitution for bladder cancer. EVIDENCE ACQUISITION: Medline, Embase, Cochrane controlled trials databases and clinicaltrial.gov were systematically searched for all relevant publications. Women with bladder cancer who underwent POPRC or standard RC and orthotopic neobladder substitution with curative intent were included. Prospective and retrospective comparative studies and single-arm case series were included. The primary outcomes were sexual function at 6-12 months after surgery and oncological outcomes including disease recurrence and overall survival (OS) at >2 years. Secondary outcomes included urinary continence at 6-12 months. Risk of bias (RoB) assessment was performed using standard Cochrane review methodology including additional domains based on confounder assessment. EVIDENCE SYNTHESIS: The searches yielded 11 941 discrete articles, of which 15 articles reporting on 15 studies recruiting a total of 874 patients were eligible for inclusion. Three papers had a matched-pair study design and the rest of the studies were mainly small, retrospective case series. Sexual outcomes were reported in seven studies with 167/194 patients (86%) having resumed sexual activity within 6 months postoperatively, with median (range) patients' sexual satisfaction score of 88.5 (80-100)%. Survival outcomes were reported in seven studies on 197 patients, with a mean follow-up of between 12 and 132 months. At 3 and 5 years, cancer-specific survival was 70-100% and OS was 65-100%. In all, 11 studies reported continence outcomes. Overall, the daytime and night-time continence rates were 58-100% and 42-100%, respectively. Overall, the self-catheterisation rate was 9.5-78%. Due to poor reporting and large heterogeneity between studies, instead of subgroup-analysis, a narrative synthesis approach was used. The overall RoB was high across all studies. CONCLUSION: For well-selected patients, POPRC with orthotopic neobladder may potentially be comparable to standard RC for oncological outcomes, whilst improving sexual and urinary function outcomes. However, in women undergoing RC, oncological and functional data regarding POPRC remain immature and require further evaluation in a prospective comparative setting.
引用
- Veskimäe E, Neuzillet Y, Rouanne M, et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int. 2017. PMID: 28220653. doi:10.1111/bju.13819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。